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Amiya Banerjee, Roger Slee, Jeanna Guenther, Bryan R. G. Williams,
Therese Wiedmer, Peter J. Sims, and Robert H. Silverman
Phospholipid scramblase 1 (PLSCR1) is an interferon (IFN)- and growth factor-inducible, calcium-binding
protein that either inserts into the plasma membrane or binds DNA in the nucleus depending on its state of
palmyitoylation. In certain hematopoietic cells, PLSCR1 is required for normal maturation and terminal
differentiation from progenitor cells as regulated by select growth factors, where it promotes recruitment and
activation of Src kinases. PLSCR1 is a substrate of Src (and Abl) kinases, and transcription of the PLSCR1
gene is regulated by the same growth factor receptor pathways in which PLSCR1 potentiates afferent signaling.
The marked transcriptional upregulation of PLSCR1 by IFNs led us to explore whether PLSCR1 plays an
analogous role in cellular responses to IFN, with specific focus on antiviral activities. Accordingly, human cells
in which PLSCR1 expression was decreased with short interfering RNA were rendered relatively insensitive to
the antiviral activity of IFNs, resulting in higher titers of vesicular stomatitis virus (VSV) and encephalomyo-
carditis virus. Similarly, VSV replicated to higher titers in mouse PLSCR1/ embryonic fibroblasts than in
identical cells transduced to express PLSCR1. PLSCR1 inhibited accumulation of primary VSV transcripts,
similar to the effects of IFN against VSV. The antiviral effect of PLSCR1 correlated with increased expression
of a subset of IFN-stimulated genes (ISGs), including ISG15, ISG54, p56, and guanylate binding proteins. Our
results suggest that PLSCR1, which is itself an ISG-encoded protein, provides a mechanism for amplifying and
enhancing the IFN response through increased expression of a select subset of potent antiviral genes.
Interferons (IFNs) are the principal cytokines responsible
for mediating innate immunity against viral infections (7). How
IFNs establish an antiviral state in cells has been a subject of
investigation since their discovery (21). Nevertheless, mecha-
nisms of IFN action against viral infections remain incom-
pletely understood. IFN antiviral studies have largely focused
on several types of IFN-stimulated genes (ISGs), including the
double-stranded RNA (dsRNA)-activated protein kinase (PKR),
human myxovirus resistance proteins (Mx), 2,5-oligoadenyl-
ate synthetase (OAS) and its effector protein RNase L, ISG56
(p56), dsRNA-specific adenosine deaminase, and guanylate
binding proteins (GBP) (35). Given the critical role of innate
immunity in survival from infections, it is not surprising that
the antiviral action of IFNs is complex and involves multiple
overlapping or related pathways. For instance, mice that are
triply deficient for RNase L, PKR, and Mx1 are nevertheless
able to mount a substantial, residual IFN antiviral response
(48). Therefore, identification of all of the antiviral ISGs is an
important step toward a more complete appreciation and un-
derstanding of innate immunity. In this regard, within the past
several years, global gene expression profiles from IFN-treated
cells, obtained by DNA microarrays, have expanded the num-
ber of known ISGs from about 33 to 200 (12, 13).
Phospholipid scramblase 1 (PLSCR1) is a novel ISG iden-
tified as such by way of DNA microarray analysis and con-
firmed by detailed analysis of the PLSCR1 promoter (12, 49,
50). In fact, PLSCR1 is highly induced by IFN-, -, and - and
also by various growth factors, including epidermal growth
factor (EGF), stem cell factor, and granulocyte colony-stimu-
lating factor (30, 51). PLSCR1 is a multiply palmitoylated,
lipid-raft-associated endofacial plasma membrane protein,
with a proline-rich cytoplasmic domain containing several SH3
and WW domain binding motifs (38). PLSCR1 is proposed to
accelerate bidirectional movement of plasma membrane phos-
pholipids during conditions of elevated calcium (50). Trans-
membrane movement of phospholipids in response to calcium,
however, is unaffected by either IFN treatment or PLSCR1
deletion (14, 49, 51).
Although the precise biologic function(s) of PLSCR1 and its
related isoforms PLSCR2 to 4 remain to be determined (38),
recent studies provide intriguing evidence of a role in cell
signaling, maturation, and apoptosis. For instance, prolifer-
ation and terminal differentiation of certain hematopoietic
stem cells (granulocyte precursor) populations is impaired in
PLSCR1-null mice (51), and in both monocytic and granulo-
cytic lineages, expression of this protein markedly increases
with terminal differentiation into polymorphonuclear leuko-
cytes or macrophages. Conversely, mutations affecting murine
PLSCR1 have been associated with a leukemogenic pheno-
type, which is reversed upon expression of the wild-type (full-
length) protein (24, 25). PLSCR1 suppressed ovarian carci-
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noma in an animal model (37), and elevated expression of
PLSCR1 has been shown to be required for normal myeloid
differentiation (51). Finally, there is recent evidence that the
level of expression of this protein correlates with overall sur-
vival in acute myelogenous leukemia (46). PLSCR1 is phos-
phorylated by select protein kinases, including Abl and Src,
tyrosine kinases that participate in multiple growth factor re-
ceptor signaling pathways (30, 32, 41). Tyrosine phosphor-
ylation of PLSCR1 by c-Src occurs in response to growth
factors such as EGF, resulting in association of phosphory-
lated PLSCR1 with Shc and the activated EGF receptor
complex (30). In the absence of PLSCR1, the activation of
c-Src kinase through EGF receptor (and related receptors)
is markedly attenuated, suggesting that PLSCR1 plays a role
in growth factor-dependent recruitment or activation of c-
Src kinase, potentially through its interaction in membrane
lipid rafts (30, 40). Palmitoylation of PLSCR1 is required for
insertion into the plasma membrane (44). However, when pal-
mitoylation does not occur, the importin / nucleopore trans-
port system has recently been shown to import PLSCR1 into
the nucleus where it binds DNA (6, 44). Accordingly, newly
synthesized PLSCR1 appeared in nuclei after IFN induction of
PLSCR1 in the human ovarian carcinoma cell line, Hey1B
(44). PLSCR1 is the only member of the PLSCR family thus
far shown to be inducible by IFNs. These findings raise the
possibility that PLSCR1 may contribute to the antiviral effects
of IFNs by affecting viral penetration, IFN-stimulated cell sig-
naling pathways at the plasma membrane, the transcription of
antiviral genes in the nucleus, and/or by directly blocking spe-
cific stages in the viral replication cycle. To determine the
involvement of PLSCR1 in the IFN-induced antiviral state,
we have compared viral replication in wild-type and
PLSCR1/ mouse cells as well as in human cells in which
PLSCR1 levels were decreased with short interfering RNA
(siRNA). Our results demonstrate a marked suppression of
viral replication by PLSCR1 which is accompanied by the en-
hanced expression of a specific subset of antiviral ISGs.
MATERIALS AND METHODS
Cell lines. The methods for establishment of mouse embryonic fibroblasts
(MEFs) from C57BL/6  SVev129 mice were previously described (30). Briefly,
primary MEFs were isolated from embryos of PLSCR1/ mice (51) or wild-type
mice and immortalized by transfection with plasmid simian virus 40 large T
antigen cDNA-pSV2 (KO1, PLSCR1/, and wild-type cells). Mouse PLSCR1
(mPLSCR1) cDNA was cloned into a modified murine stem cell virus (MSCV)-
internal ribosome entry site (IRES)-green fluorescence protein (GFP) vector,
MSCV-IRES-GFP (derived from a plasmid generously provided by Ruibao Ren,
Brandeis University), and transfected into the packaging cell line, PT-67 (BD
Clontech), to yield infectious virus. mPLSCR1-MSCV-IRES-GFP was con-
structed as follows: v-abl-MSCV-IRES-GFP was digested with EcoRI and
BamHI to remove v-abl cDNA. An SfiI cutting site (GGCCGCCTCGGCC) was
inserted into the multiple cloning site of the MSCV-IRES-GFP vector by PCR-
mediated insertion. mPLSCR1 cDNA was cloned into the EcoRI and SfiI sites of
the modified MSCV-IRES-GFP vector. The KO1 MEFs were infected with
MSCV-mPLSCR1-IRES-GFP virus to generate KI cells, or control MSCV-IRES-
GFP virus was used to infect KO1 cells to generate KO2 cells. Infected cells were
sorted by flow cytometry with GFP as an indicator to collect cells with similar
expression levels of GFP. The expression of PLSCR1 was confirmed by Western
blotting with monoclonal antibody against mPLSCR1(1A8) (30). The human
ovarian carcinoma cell line Hey1B (a gift from Alexander Marks, University of
Toronto, and Yan Xu, Cleveland Clinic) (4) and mouse L929 and NIH 3T3 cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with streptomycin-penicillin and 10% heat-inactivated fetal bovine serum (FBS).
Hey1B cells stably expressing siRNA were established as described previously
(10). Plasmid pSUPERhPLSCR1 was generated by cloning a 19-nucleotide se-
quence (beginning 92 nucleotides from the translation start site in the human
PLSCR1 [hPLSCR1] mRNA) separated by a spacer from its reverse complement
as a BglII/HindIII fragment (synthesized at Invitrogen) into the pSUPER vector,
which directs synthesis of an RNA from the H1-RNA promoter that is processed
in the cell to siRNA (10). The sequences for primers of siRNA of hPLSCR1 are
5-GAT-CCC-CGG-ACC-TCC-AGG-ATA-TAG-TGT-TCA-AGA-GAC-ACT-
ATA-TCC-TGG-AGG-TCC-TTT-TTG-GAA-A-3 and 3-GG-GCC-TGG-
AGG-TCC-TAT-ATC-ACA-AGT-TCT-CTG-TGA-TAT-AGG-ACC-TCC-
AGG-AAA-AAC-CTT-TTC-GA-5. The sequences for primers of the mismatch
control are 5-GAT-CCC-CGG-ACG-TCC-TGG-ATT-TAG-TGT-TCA-AGA-
GAC-ACT-AAA-TCC-AGG-ACG-TCC-TTT-TTG-GAA-A-3 and 3-GG-
GCC-TGC-AGG-ACC-TAA-ATC-ACA-AGT-TCT-CTG-TGA-TTT-AGG-
TCC-TGC-AGG-AAA-AAC-CTT-TTC-GA-5 (mismatched nucleotides are
underlined). The oligonucleotides were annealed by incubation in 100 mM
potassium acetate, 30 mM HEPES-KOH (pH 7.4), and 2 mM magnesium ace-
tate at 95°C for 4 min and then at 70°C for 10 min. The reaction mixtures were
slowly cooled to 4°C, and annealed oligonucleotides were phosphorylated with
T4 polynucleotide kinase at 37°C for 30 min and incubated at 70°C for 10 min.
Ligation of the oligonucleotides was to pSUPER digested with BglII and Hin-
dIII. The vectors containing siRNA to hPLSCR1, the 3-base mismatch control,
and empty vector were each cotransfected with plasmid pBABE containing a
puromycin resistance gene (10) into Hey1B cells by using Lipofectamine 2000
(Invitrogen). Stable cell lines were selected by continuous culturing in media
containing 2 	g of puromycin per ml. PLSCR1 expression levels in cell lines were
determined on Western blots probed with rabbit anti-hPLSCR1 peptide 306-318
antibody (50) and anti-rabbit immunoglobulin G (IgG) horseradish peroxidase
(HRP)-linked (Cell Signaling) and -actin monoclonal antibodies (Sigma Co.).
Forty-seven clones expressing siRNA to PLSCR1 were isolated and screened by
Western blot assays, of which about 20 clones had PLSCR1 protein levels that
were 2-fold that of untreated parental cells. The siRNA clone that had the
lowest level of PLSCR1 was used in these studies. In addition, individual clones
containing the empty vector and the vector expressing the mismatch siRNA were
isolated and determined by Western blotting to have PLSCR1 levels that were
similar to those of the parental cells.
VSV purification and infections. Wild-type vesicular stomatitis virus (VSV)
and an M protein late-budding domain or PY motif mutant (AAPA) (both were
the Indiana strain) were propagated in BHK-21 cells (17). VSV was either from
infected cell supernatant or was purified by sucrose gradient sedimentation (3) as
indicated in the text. Briefly, virus in culture medium was pelleted by ultracen-
trifugation at 80,000 g in a Beckman Rotor SW 41 or SW 28 for 120 min at 4°C.
Virus pellets were suspended in phosphate-buffered saline (PBS) for 16 h at 4°C,
loaded onto 0 to 40% sucrose gradients in 50 mM Tris-HCl (pH 7.6), 250 mM
NaCl, and 0.5 mM EDTA, and centrifuged at 35,000  g in a Beckman rotor SW
41 for 90 min. The clear, white layer containing virus was collected and sus-
pended in PBS at 4°C overnight, and the purified virus was stored at 70°C. All
virus titers were determined by plaque assay (45) on soft agar overlays of L929
cells in six-well plates for incubation at 37°C for 1 to 2 days.
VSV infections were done after seeding cells in six-well plates (at 3  105 to
4  105 cells per well) and incubating them at 37°C in 5% CO2 overnight. Cells
were washed once with PBS and infected with a 0.1 multiplicity of infection
(MOI) of VSV in FBS-free DMEM (Invitrogen) for 1 h followed by replacement
of media with DMEM–10% FBS for different periods of time as indicated in the
text. Cells were lysed with buffer containing 1% Triton X-100, 25 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 1% sodium deoxycholate, and 10 ng of leupeptin per ml,
and extracts were centrifuged at 16,000  g for 20 min. Media from infected cells
were assayed for virus by plaque assays or for viral proteins in media of infected
cells or supernatant of the cell lysates by Western immunoblot assays.
Immunoblots. Rabbit antibody 4720 against N-terminal residues 1 to 12 of
mPLSCR1 (41) and rabbit antibody against C-terminal residues 306 to 318 of
hPLSCR1 (50) were previously described (each are rabbit antipeptide antisera
that are affinity purified on the peptide and thus used as affinity-purified IgG).
Other antibodies used were rabbit anti-N protein of VSV (8), rabbit anti-L
protein of VSV raised against a synthetic peptide corresponding to amino-
terminal residues 5 to 19 of the L protein (29), mouse monoclonal anti-VSV M
protein (a gift from D. S. Lyles, Winston-Salem, N.C.), mouse monoclonal anti-
VSV G protein (no. 1667351; Roche), rabbit anti-p56 (a gift from Ganes Sen,
Cleveland, Ohio) (16), mouse monoclonal anti-p15 (from Ernest Borden, Cleve-
land, Ohio) (11), rabbit anti-mGBP-2 (from Deborah Vestal, Toledo, Ohio) (42),
and monoclonal anti--actin (catalog number A-5441; Sigma Co.). Proteins (30
to 60 	g) in cell extracts or 25 	l of medium from virus-infected cells was
separated on 8 to 12% polyacrylamide–sodium dodecyl sulfate (SDS) gels and
transferred onto Immobilon-P transfer membranes (Millipore Co.). Blots were
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blocked with PBS containing 0.07% Tween (PBS-T) and 5% fat-free dried milk
for 1 h and then incubated with primary antibodies in the same blocking buffer
at room temperature for 2 h or at 4°C for 16 h. The blots were washed three times
with PBS-T. After a 1-h incubation of blots with secondary antibody, anti-mouse
IgG-HRP, or anti-rabbit IgG-HRP (Cell Signaling Co.) and four washes with
PBS-T, protein bands were visualized with enhanced chemiluminescence detec-
tion reagents (Amersham Co.). Protein amounts were estimated with the NIH
Image (version 1.61) computer program.
VSV adsorption and penetration. The 35S-labeled VSV was prepared from 2
107 BHK-21 cells infected with VSV (MOI 
 0.1) in methionine-free DMEM
(Invitrogen Co.) in the absence of serum for 1 h and washed with PBS. Methi-
onine-free DMEM containing both 3 	g of actinomycin D per ml and 1.4 mCi of
[35S]methionine was added to the cells, and cells were incubated for 24 h. The
35S-labeled VSV in the media was purified by sucrose gradient sedimentation as
described above. KO and KI cells were plated 1 day prior to infection in 12-well
plates with 6  104 cells per well and incubated with purified 35S-labeled VSV
(MOI 
 4) in FBS-free DMEM at 37°C for 1 h. After cells were washed twice
with PBS, complete DMEM with 10% FBS was added and cells were incubated
for 1.5 h. Lysis buffer was added to the cells after the cells were washed three
times with PBS. The cell lysates were centrifuged at 16,000  g for 20 min, the
protein extracts were fractionated on 10% polyacrylamide–SDS gels, and an
autoradiogram was prepared from the dried gels. Radiolabeled viral protein
amounts were estimated by using NIH Image (version 1.61).
Primary VSV mRNA transcript accumulation. VSV N mRNA accumulation
owing to primary transcription was measured as described previously (8). KO2
and KI cells were pretreated with 1,000 U of recombinant human IFN- A/D
(Hoffmann LaRoche, Inc.) per ml for 16 h and washed with PBS once. Cyclo-
heximide (10 	g/ml) in DMEM with 10% FBS was added to the cells for 2.5 h
followed by washing with PBS. Purified VSV at an MOI of 0.5 with FBS-free
DMEM and 10 	g of cycloheximide/ml was added to the cells for 1 h. After
removing the virus, cells were incubated with 10% FBS–DMEM with cyclohex-
imide (10 	g per ml) for 3, 5, and 8 h before cells were harvested for RNA
extraction with Trizol (Invitrogen). RNA (10 	g) was separated on 1.2% agar-
ose–formaldehyde gels, transferred to a Hybond-N membrane (Amersham
Biosciences), and cross-linked with UV. The blots were incubated with ULTRA-
hyb (Ambion) hybridization buffer at 42°C for 4 h, prior to the addition of
32P-cDNA, encoding the VSV N protein (8, 20, 33), which was labeled by using
the Prime-a-Gene system (Promega) at 42°C for 16 h. The autoradiograms of the
blots were prepared after washing four times at 50°C in 2 SSC (1 SSC is 0.15
M NaCl plus 0.015 M sodium citrate) with 0.1% SDS. The blots were stripped
and reprobed with 32P-labeled -actin cDNA.
EMCV infections. Encephalomyocarditis virus (EMCV) (a gift of I. Kerr,
London, England) was propagated by infecting L929 cells, collecting the cell
supernatants, and clearing by centrifugation at 16,000  g for 20 min at 4°C.
Virus titers were determined by plaque assays with L929 cells. EMCV was used
to infect cells at an MOI of 0.01, in FBS-free DMEM for adsorption (1 h), which
was then replaced with 10% FBS–DMEM. The media containing progeny virus
were collected after 24 and 40 h.
Gene expression profiling by use of custom cDNA microarrays. Cells stably
expressing siRNA to hPLSCR1 and mismatch control and vector control cells
were plated in triplicate at 4  105 cells per well in six-well plates and incubated
at 37°C with 5% CO2 for 16 h. Cells were incubated in the absence and presence
of 1,000 U of human IFN- (Interpharma) per ml for 8 h and washed with PBS.
Total RNA was extracted with Trizol reagent while identically treated cells were
harvested for determining PLSCR1 levels.
Array construction. The array used in this study comprised a subset of se-
quence-verified cDNA clones from the Research Genetics, Inc., 40,000-clone set
representing 950 genes containing adenylate-uridylate-rich elements and 18 genes
potentially involved in AU-directed mRNA decay as previously described (15), 855
ISGs representing an expansion of a previously described clone set containing
confirmed and candidate genes stimulated by IFNs in diverse cell types (13), 288
genes responsive to the viral analog poly(I-C), and 85 housekeeping genes. DNA
preparation and slide printing were as previously described except for the use of
40% dimethyl sulfoxide in place of 1.5 SSC as the printing solution (15).
Target RNA preparation. Target RNA was generated in a T7 polymerase-
based linear amplification reaction based on a modified version of a published
protocol (43). Two micrograms of total RNA and 5 pmol of T7-(dT)24 primer
[5-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-
3] in a total volume of 5.5 	l was incubated at 70°C for 10 min and chilled on
ice. For first-strand cDNA synthesis, the annealed RNA template was incubated
for 1 h at 42°C in a 10-	l reaction mixture containing first-strand buffer (Invitro-
gen), 10 mM dithiothreitol, 1 U of anti-RNase (Ambion) per 	l, 500 	M
deoxynucleoside triphosphates, and 2 U of Superscript II (Invitrogen) per 	l.
Second-strand synthesis was for 2 h at 16°C in a total reaction volume of 50 	l
containing first-strand reaction products, second-strand buffer (Invitrogen), 250
	M deoxynucleoside triphosphates, 0.06 U of DNA ligase (Ambion) per 	l, 0.26
U of DNA polymerase I (New England Biolabs) per 	l, and 0.012 U of RNase
H (Ambion) per 	l followed by the addition of 3.3 U of T4 DNA polymerase (3
U per 	l; New England Biolabs) and a further 15 min of incubation at 16°C.
Second-strand reaction products were purified by phenol-chloroform-isoamyl
alcohol extraction in Phaselock microcentrifuge tubes (Eppendorf) according to
the manufacturer’s instructions and ethanol precipitated. In vitro transcription
was performed by using the T7 megascript kit (Ambion) according to a modified
protocol in which purified cDNA was combined with 1 	l (each) of 10 ATP,
GTP, CTP, and UTP and 1 	l of T7 enzyme mix in a 10-	l reaction volume and
incubated for 9 h at 37°C. Amplified RNA was purified by using the Rneasy RNA
purification kit (Ambion) according to the manufacturer’s instructions.
RNA labeling. Cy3- or Cy5-labeled cDNA was prepared by indirect incorpo-
ration. Two micrograms of amplified RNA, 1 	l of dT12-18 primer (1 	g per 	l;
Invitrogen), 2.6 	l of random hexanucleotides (3 	g per 	l; Invitrogen), and 1 	l
of anti-RNase (Ambion) were combined in a reaction volume of 15.5 	l and
incubated for 10 min at 70°C. Reverse transcription was for 2 h at 42°C in a 30-	l
reaction mixture containing annealed RNA template, first-strand buffer, 500 	M
(each) dATP, dCTP, and dGTP, 300 	M dTTP, 200 	M aminoallyl-dUTP
(Sigma), 10 mM dithiothreitol, and 12.7 U of Superscript II per 	l. For template
hydrolysis, 10 	l of 0.1 M NaOH was added to the reverse transcription reaction
mixture and the mixture was incubated for 10 min at 70°C, allowed to cool at
room temperature for 5 min, and neutralized by the addition of 10 	l of 0.1 M
HCl. cDNA was precipitated at 20°C for 30 min after the addition of 1 	l of
linear acrylamide (Ambion), 4 	l of 3 M sodium acetate (pH 5.2), and 100 	l of
absolute ethanol, and then resuspended in 5 	l of 0.1 M NaHCO3. For dye
coupling, the contents of 1 tube of N-hydroxysuccinimide ester containing Cy3 or
Cy5 dye (product no. PA25001 and PA25002; Amersham Biosciences) was dis-
solved in 45 	l of dimethyl sulfoxide. Five microliters of dye solution was mixed
with the cDNA and incubated for 1 h in darkness at room temperature. Labeled
cDNA was purified on a QIAquick PCR purification column (QIAGEN) ac-
cording to the manufacturer’s instructions. Eluted cDNA was dried under a
vacuum and resuspended in 30 	l of Slidehyb II hybridization buffer (Ambion).
After 2 min of denaturation at 95°C, the hybridization mixture was applied to the
microarray slide under a coverslip. Hybridization proceeded overnight in a
sealed moist chamber in a 55°C water bath. Posthybridization, slides were washed
successively for 5 min each in 2 SSC–0.1% SDS at 55°C, then in 2 SSC at
55°C, and finally, in 0.2 SSC at room temperature.
Acquisition and normalization of data. Data were acquired with a GenePix
4000B laser scanner and GenePix Pro, version 5.0, software as previously de-
scribed (15). Raw data were imported into GeneSpring, version 6.0, software
(Silicon Genetics) and normalized based on the distribution of all values with
locally weighted linear regression before further analysis.
RESULTS
PLSCR1 contributes to antiviral activities of IFNs. To in-
vestigate the involvement of PLSCR1 in the IFN-induced an-
tiviral state, PLSCR1 levels were stably decreased in the hu-
man ovarian carcinoma cell line Hey1B by using an siRNA
approach. An siRNA against a PLSCR1 mRNA target site, 92
to 110 nucleotides 3 to the translation start site, was generated
from a DNA sequence cloned into plasmid pSUPER (10). As
a control, siRNA was generated with 3 mismatched nucleo-
tides to the same PLSCR1 sequence and with compensatory
base changes in the opposite strand to maintain base pairing.
In addition, cells containing the empty plasmid vector were
also used as controls. Extracts of stable clones obtained by drug
selection were screened for PLSCR1 expression in Western
blots probed with antibodies to both PLSCR1 and -actin. Cell
lines with empty vector (vector control) and with the mismatch
siRNA showed similar basal levels of PLSCR1 that increased
markedly with IFN- treatment (Fig. 1A, lanes 1 to 4). In con-
trast, the PLSCR1 siRNA plasmid reduced the basal expres-
sion of PLSCR1 by about 10-fold (relative to basal expression
in untreated controls). Furthermore, the IFN-induced level of
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PLSCR1 was also suppressed severalfold through PLSCR1-
specific siRNA compared to the IFN-stimulated controls not
containing the PLSCR1 siRNA plasmid (Fig. 1A, top panel,
compare lanes 2, 4, and 6).
To investigate the potential antiviral effect of PLSCR1, cells
were incubated in the presence or absence of IFN- (1,000 U
per ml) for 8 h and subsequently infected with the VSV Indi-
ana strain at an MOI of 0.1 (a member of the Rhabdoviridae
family of enveloped, nonsegmented negative-strand RNA vi-
ruses). Levels of VSV N protein and p56 (encoded by an ISG)
were determined at 24 h postinfection (Fig. 1A). VSV N pro-
tein amounts were greatly reduced by IFN- in both the vector
control and siRNA mismatch-expressing cells (Fig. 1A, lanes 1
to 4). Remarkably, however, N protein levels appeared only
slightly decreased after IFN- treatment of cells with siRNA to
PLSCR1 (Fig. 1A, lane 6). Furthermore, reducing the PLSCR1
levels resulted in increases of VSV yields (about 1 log10 unit)
by 16 h but not at 24 h postinfection, possibly indicating that
PLSCR1 was causing a delay in the replication cycle (Fig. 1B).
The antiviral effect of IFN- at both 16 and 24 h postinfection,
however, was substantially impaired when PLSCR1 levels were
decreased (Fig. 1B). At 24 h postinfection, IFN- reduced
FIG. 1. Decreasing levels of PLSCR1 with siRNA suppresses the anti-VSV activity of IFN in human Hey1B cells. Hey1B cells stably transfected
with pSUPER lacking insert (vector control) or pSUPER expressing the siRNA mismatch control or siRNA to PLSCR1 were incubated with or
without human IFN- (1,000 U per ml) for 8 h and were then infected with purified VSV at an MOI of 0.1 for 16 and 24 h. (A) Levels of hPLSCR1,
VSV N protein, p56, and -actin were determined at 24 h postinfection from cell extracts in Western blots probed with antibodies. (B) VSV yields
were determined by plaque assays after combining media from triplicate cultures of infected cells preincubated in the presence () or absence ()
of IFN- (as indicated).
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VSV yields by about 200-fold in the vector control and siRNA
mismatch cells, whereas the IFN effect was only 5-fold in the
cells expressing PLSCR1 siRNA (Fig. 1B). To monitor IFN
induction of gene expression, levels of p56 protein were mea-
sured with a monoclonal antibody. IFN- treatment of both
the empty vector and mismatch siRNA control cells induced p56
to severalfold-higher levels than in the IFN-treated PLSCR1
siRNA cells (Fig. 1A, lanes 2, 4, and 6). The effect of PLSCR1
on p56 expression required the addition of exogenous IFN and
was not observed with virus alone. These results suggested a
possible contribution of PLSCR1 to IFN induction of gene
expression. There was no increase of p56 expression in the
control siRNA-expressing cells (Fig. 1A, compare lanes 1 and
3), suggesting that pSUPER expression of siRNA in these cells
did not produce an off-target, nonspecific effect on ISG expres-
sion (9, 39). This conclusion was supported by gene array
results (see below).
To determine whether the antiviral activity of PLSCR1 was
specific for VSV, growth of EMCV (a member of the Picor-
naviridae family of nonenveloped, positive-strand RNA vi-
ruses) was compared in the different cell lines (Fig. 2). The
Hey1B cells were incubated in the presence or absence of
human IFN- (1,000 U per ml) for 8 h and then infected with
EMCV at an MOI of 0.01. In the absence of IFN, suppression
of basal PLSCR1 expression by specific siRNA resulted in an
about 10-fold increase in viral replication at 24 h postinfection,
FIG. 2. PLSCR1 suppresses EMCV replication in Hey1B cells.
Hey1B cells stably transfected with empty vector (vector control, white
bars) or with vector expressing mismatched siRNA (hatched bars) or
PLSCR1 siRNA (black bars) were treated with IFN- (1,000 U per ml)
for 8 h and infected with EMCV (MOI of 0.01) for 24 and 40 h. Viral
titers from combining media of triplicate infected cultures of cells were
determined by plaque assays. , present; , absent.
FIG. 3. PLSCR1 enhances expression of a set of ISGs as determined in DNA microarrays. Hey1B cells expressing siRNA mismatch or siRNA
to PLSCR1 were incubated with or without IFN- (1,000 U/ml) for 8 h. Gene array results are from RNA samples isolated from triplicate cultures
of IFN-treated or control cells. Numbers represent increases (n-fold) in RNA levels after IFN treatment.
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although no effect was seen at 40 h, suggesting a small delay in
viral replication due to PLSCR1. In contrast to these small
effects in the absence of IFN, in cells pretreated with IFN, the
suppression of PLSCR1 expression by specific siRNA elimi-
nated most of the observed antiviral activity associated with
addition of IFN (cf. black bars to controls in Fig. 2).
Reduced expression of ISGs in PLSCR1-deficient cells. Our
findings suggest a general antiviral effect of PLSCR1 that ap-
pears related to marked enhancement of the cellular response
to IFN. We therefore next compared mRNA profiles in un-
treated and IFN--treated cells by using a custom viral re-
sponse cDNA microarray constructed with 855 candidate and
confirmed ISGs, 950 AU-rich element genes, 288 dsRNA-stim-
ulated genes, and 85 housekeeping genes, with the latter serv-
ing as mRNA controls (Fig. 3). Triplicate cultures of Hey1B
vector control, mismatch siRNA, or PLSCR1 siRNA clones
were treated with IFN- at 8 h, and the RNA isolated from
identically treated cultures was combined for microarray anal-
ysis. The experiment was independently performed twice (i.e.,
experiments A and B were both from RNA pools of triplicate,
identically treated cultures). In addition, several of the ISGs
were present at multiple positions on the array (indicated by
multiple rows for the same gene in Fig. 3). Twenty-four genes
were more-highly induced by IFN- in the control cells ex-
pressing mismatched siRNA than in the cells expressing spe-
cific siRNA to PLSCR1. Twenty-one of these genes are previ-
ously identified ISGs. Three genes are newly identified ISGs
from these experiments and are also AU-rich genes (hypothet-
ical protein expressed in osteoblasts, TEB4, and transcription
factor AP-2 gamma). ISG54, present at three locations on the
array, was one of the most highly elevated ISGs associated with
PLSCR1 expression. The average IFN induction of ISG54 was
about fivefold greater in the control siRNA cells than in the
PLSCR1 siRNA cells. The remaining 23 ISGs were induced
1.7- to 5-fold greater by IFN in the control siRNA cells than
in the PLSCR1 siRNA-expressing cells. Our results suggest a
contribution of PLSCR1, a known ISG (12, 49), to the IFN-
stimulated expression of a limited subset of ISGs. However,
because siRNA ablation of PLSCR1 was incomplete, the val-
ues obtained may underestimate the contribution of PLSCR1
to ISG expression. A decreased IFN induction of PLSCR1
itself was observed in the siRNA to PLSCR1 cells. PLSCR1
siRNA did not significantly affect expression of any of the 85
housekeeping genes serving as controls (data not shown).
To confirm the gene array results, immunoblot measure-
ment of several different IFN-induced proteins was performed
(Fig. 4). Deficient IFN induction of PLSCR1, p56, and ISG15
was observed; there was a small effect on Stat1 levels while
PKR and RNase L amounts were essentially unaffected. The
siRNAs by themselves did not induce ISG expression, as de-
termined by both gene microarrays and Western blot assays
(Fig. 4 and data not shown).
The IFN response is reduced in PLSCR1/ MEFs. To per-
form studies in the complete absence of PLSCR1, PLSCR1/FIG. 4. PLSCR1 enhances the expression of a subset of ISGs as
determined by Western immunoblots. Hey1B cells containing empty vec-
tor (vector) or expressing siRNA mismatch or siRNA to PLSCR1 were
incubated with () or without () IFN- (1,000 U/ml) for 16 h. Levels
of proteins (indicated) were determined by probing Western blots of
cell extracts with specific antibodies (see Materials and Methods).
FIG. 5. VSV replicates to higher titers in MEFs lacking PLSCR1.
(A) Wild-type (black bars) and PLSCR1/KO1 (white bars) MEFs
were infected with VSV at an MOI of 0.1. (B) PLSCR1/ KO2 (white
bars) MEFs and reconstituted, PLSCR1-expressing knock-in KI cells
(black bars) were infected with VSV at an MOI of 0.1. At different
times postinfection (x axes), virus was harvested. Viral yields, deter-
mined by plaque assays on indicator L929 cells, were from combined
triplicate cultures of infected cells.
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MEFs immortalized with simian virus 40 large T antigen (KO1
cells) were utilized. VSV yields were increased up to about
100-fold in the KO1 cells compared to the wild-type cells (Fig.
5A). To rule out nonspecific effects owing to clonal variations,
the KO1 cells were transfected with MSCV vector expressing
PLSCR1 cDNA (KI cells for gene knock-in) or with an empty
MSCV vector (KO2 cells). VSV yields were 3 to 4 log10 units
higher in the KO2 cells than in KI cells (Fig. 5B). These results
from KO cells deficient in PLSCR1 are consistent with results
obtained with wild-type cells in which endogenous PLSCR1
expression was suppressed by siRNA, although the PLSCR1-
related antiviral effect was even more apparent in the former,
where PLSCR1 is completely absent.
Determining the stage(s) in the VSV replication cycle af-
fected by PLSCR1. To examine how PLSCR1 affects VSV
replication, several distinct stages in the viral life cycle were
analyzed and compared in the KO2 and KI cells. Viral absorp-
tion and penetration were determined by infecting cells with
purified 35S-labeled VSV for 2.5 h and monitoring cell-associ-
ated proteins that originated from the input virus. After wash-
ing and lysing the infected cells, proteins were subjected to
electrophoresis, transfer, and autoradiography (Fig. 6). Equiv-
alent amounts of the 35S-labeled VSV proteins, G (glycopro-
tein), N (nucleoprotein), and M (matrix protein), were ob-
served associated with the KO2 and KI cells. These results
suggest that PLSCR1 did not affect stages prior to viral pene-
tration.
Primary viral transcript accumulation was monitored by
measuring VSV N mRNA produced from the input genome in
the presence of cycloheximide. This method relies on the fact
that amplification of VSV RNA, but not primary transcription,
requires ongoing protein synthesis. Previously, IFN was re-
ported to suppress VSV replication at the level of viral primary
transcription (5). In the present studies, IFN- pretreatments
effectively reduced primary viral transcript accumulation in
both cell lines (Fig. 7). Furthermore, expression of PLSCR1
reduced N mRNA accumulation in either the absence or
presence of prior IFN treatment. Therefore, both IFN and
PLSCR1 suppressed VSV replication at the level of primary
transcript accumulation. Accordingly, in cells infected in the
absence of cycloheximide, VSV L, G, N, and M proteins were
significantly more abundant in the media (from released virus)
and from intact KO2 cells than were released virus and cell-
associated virus of the KI cells (Fig. 8). An additional effect on
viral protein synthesis is not ruled out by these findings (34).
To determine whether late stages in the virus replication
cycles were affected by PLSCR1, release of progeny wild-type
VSV and of a late-budding domain (PPPY to AAPA) M pro-
tein mutant virus into the media was compared in the KO2 and
KI cells. The M protein mutation was previously observed to
reduce viral release by about 1 to 2 log10 units (23). Similarly,
the AAPA mutant form of M protein reduced viral yields by
45-fold in the KO2 cells and by 62-fold in the KI cells (Fig. 9).
These results suggest that the anti-VSV effect of PLSCR1 does
not depend on or require the late-budding PY domain in M
protein but does not exclude the possibility that PLSCR1 may
FIG. 6. Adsorption and penetration of 35S-labeled VSV is unaf-
fected by PLSCR1. KO2 (PLSCR1/) and KI (PLSCR1 reconsti-
tuted) cells were infected with purified 35S-VSV (MOI of 4) (see
Materials and Methods). Cell-associated proteins were separated by
SDS-polyacrylamide gel electrophoresis, and an autoradiogram of the
dried gel was prepared. The positions of the VSV G, N, and M proteins
are indicated (arrows).
FIG. 7. PLSCR1 and IFN- inhibit accumulation of primary VSV N transcripts. Cells were incubated with or without IFN- A/D (1,000 U per
ml) for 16 h followed by treatment with cycloheximide (3 	g/ml) for 2.5 h. Infections were with purified VSV (MOI of 0.5) for 0, 3, 5, and 8 h in
the continuous presence of cycloheximide to prevent replication. The Northern blot was probed with 32P-cDNA to the N gene of VSV and was
normalized with a radiolabeled cDNA to -actin.
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influence viral budding, for example, through effects on plasma
membrane lipid organization or topology.
PLSCR1 expression was equivalent in the wild-type and KI
cells and was absent in the KO1 and KO2 cells (Fig. 10 and
data not shown). In the wild-type cells, PLSCR1 levels were
constitutively elevated and were not further increased by IFN-
 treatment, perhaps due to induction by growth factors in the
serum (51) (Fig. 10, lanes 4 to 6). Cell-type-specific differences
in basal levels of PLSCR1 may reflect inherent lineage or
maturational differences in PLSCR1 expression as well as dif-
fering sensitivities of the cells to induction by growth factors or
interferon. GBP-2 was induced by 10-fold-lower concentra-
tions of IFN- in the wild-type and KI cells than in the KO1
cells (Fig. 10) (42). However, IFN-induced levels of PKR and
STAT1 were similar in the different cell lines. Basal levels of
PKR, however, were modestly elevated in untreated confluent
(24 h) cultures of PLSCR1-expressing cells compared with
KO1 cells (Fig. 10, bottom, lanes 1, 4, and 7). These findings
are consistent with the notion that PLSCR1 affects the expres-
sion of only a limited subset of ISGs.
DISCUSSION
Our results suggest that the expression of PLSCR1, an ISG,
is required for maximal antiviral activity of IFN, and that this
effect is mediated at least in part through potentiation of the
expression of a select subset of ISGs with known or suspected
antiviral activities. However, PLSCR1 is nonessential for IFN
signaling because IFN strongly induces PKR and STAT1 in
PLSCR1/ cells (Fig. 10). Whereas the precise mechanism by
which PLSCR1 exerts these selective effects on certain ISGs
remains unresolved, it is of note that (i) PLSCR1 is a palmi-
toylated, plasma membrane protein known to partition into
lipid rafts and implicated in regulating the organization of
plasma membrane phospholipids (38, 40), (ii) deletion of
PLSCR1 has been shown to alter afferent signaling and cellular
response to a select group of cell surface growth factor recep-
tors with specific effects on the activation of c-Src and poten-
tially other protein kinases (30, 32, 41), (iii) in addition to
transcriptional induction by IFN, PLSCR1 expression is up-
regulated through each of the growth factor receptor pathways
that PLSCR1 gene deletion has been shown to attenuate af-
ferent receptor signaling (30, 51), (iv) under conditions of
transcriptional induction, PLSCR1 has been shown to traffic to
both the plasma membrane and the nucleus, events that appear
to be regulated through its palmitoylation (44), and (v) once in
the nucleus, PLSCR1, an acidic polypeptide, is found tightly
bound to DNA (6). Taken together, this suggests that the
observed antiviral activity of PLSCR1 and its capacity to po-
tentiate transcription of a select subset of ISGs reflects activ-
ities of this protein at the plasma membrane that potentially
influence afferent signaling through the JAK/STAT kinase
pathway (or accessory signaling pathways recruited down-
stream of the activated receptor), resulting in alteration of the
FIG. 8. VSV protein accumulation is reduced in cells expressing PLSCR1. KO2 and KI cells were infected with purified VSV at an MOI of 0.1
for 5, 8, and 11 h (as indicated). Levels of VSV proteins from released virus (Media) and associated with intact cells (Cells) were determined on
Western blots probed with antibodies to the VSV L, G, N, and M proteins.
FIG. 9. Replication of VSV with a late-budding domain mutation
(AAPA) in the M protein and wild-type VSV were similarly inhibited
by PLSCR1. KO2 (white bars) and KI (black bars) cells were infected
with wild-type VSV and VSV-AAPA mutant virus (MOI of 0.1) for
16 h. The viral yields in the media combined from three separate
infections of cells were determined by plaque assays on indicator cells.
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repertoire of activated transcription factors, and/or effects of
nuclear PLSCR1 on the transcription of select ISGs.
Regarding the specific ISGs positively regulated by PLSCR1,
the virus stress-inducible proteins p54 and p56 (encoded by
ISG54 and ISG56, respectively) are related members of a pro-
tein family containing tetratricopeptide motifs (19). Protein
p56 interacts with the protein synthesis initiation factor ε sub-
unit of eukaryotic initiation factor 3 (eIF-3ε) and inhibits trans-
lation by interfering with the binding of eIF-2–GTP–Met-
tRNAi (ternary complex) with eIF-3. Therefore, p56 has the
ability to suppress translation of virus and host proteins. The
functions of the other family members, p54, p58, and p60, are
unknown. ISG15 contains two ubiquitin homology domains
and is ligated to diverse proteins, including Jak1 and Stat1, and
has been suggested to play a positive role in IFN signaling (26,
28). The NS1 protein of influenza B virus inhibits linkage of
ISG15 to its target proteins, supporting an antiviral role for
ISG15 (47). OAS2 is one of the upstream enzymes in the
2,5-oligoadenylates (2-5A)/RNase L antiviral pathway that
synthesizes 2-5A in response to viral dsRNA. 2-5A activates
RNase L, causing breakdown of viral and host RNA (36).
RNase L/ mice are partially deficient in the anti-EMCV
effect of IFN- (48). GBP-2 and GBP-3 are members of an
IFN-induced gene family of at least five different GBPs (31,
42). GBP-1 was shown to inhibit replication of VSV and
EMCV, but the mechanism is unknown (1). Expression of
PLSCR1 was also associated with enhanced basal expression of
PKR in confluent, but not in subconfluent, mouse cells (Fig.
10). Therefore, PKR may also contribute to the observed an-
tiviral effects of PLSCR1. PKR is activated by viral dsRNA to
phosphorylate translation initiator factor eIF-2, resulting in a
cessation of protein synthesis. In addition, PKR is implicated
in inhibiting VSV replication in mice (2). However, PLSCR1
did not affect IFN-induced levels of PKR. Expression of
PLSCR1 was also associated with modestly enhanced expres-
sion of IRF7, which could potentially lead to IFN synthesis,
thus further amplifying the antiviral response (Fig. 3) (27). The
apparent enhancing effect of PLSCR1 on any particular gene
was in the range of a 1.5- to 5-fold, with the combined effect
on presumably several ISGs resulting in a significant negative
impact on virus replication.
FIG. 10. IFN-induced and basal levels of PLSCR1, GBP-2, PKR, and Stat1 in IFN-treated and control MEFs that contain or lack PLSCR1.
Cells were incubated for 8 or 24 h in the presence or absence of different concentrations of IFN- A/D (as indicated). Cells harvested at 8 and
24 h were subconfluent and confluent, respectively. Western blots probed with antibodies to PLSCR1, GBP-2, PKR, and Stat1 are shown.
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Effect of PLSCR1 on VSV replication. Although PLSCR1
appeared to enhance the expression of a number of genes, a
direct effect of this protein on virus replication is also possible.
Therefore, to determine how PLSCR1 was affecting VSV rep-
lication, we analyzed different stages in the virus cycle. The
location of PLSCR1 in the cell membrane suggested a possible
effect on virus adsorption and/or uptake. However, these steps
in the virus replication cycles were unaffected by PLSCR1. In
contrast, there was a substantial increase in primary (N) tran-
script accumulation in PLSCR1/ (KO2) cells. Reduction in
VSV primary transcript accumulation by IFN in either the
absence or presence of PLSCR1 was substantial. The effect of
PLSCR1 on VSV replication is superimposed on a larger IFN
antiviral effect. As a result, we were unable to accurately de-
termine whether the reduction by IFN in the two cell types was
comparable. Our findings are consistent with a previous report
demonstrating that IFN treatment affects VSV replication at
the level of primary transcription (5). However, different stud-
ies localized the effect of IFN against VSV to other stages in
the replication cycle, including protein synthesis (34) and virus
assembly (22). Recently, it was demonstrated that IFN inhibits
VSV entry into human epithelial cells by producing soluble
secreted antiviral factors (S. Bose and A. K. Banerjee, unpub-
lished data). Therefore, there are clearly cell-type-specific dif-
ferences in the anti-VSV mechanism of IFNs. The present
study does not rule out an effect on viral protein synthesis
because it is difficult to measure an effect on protein synthesis
when there is potent inhibition of viral primary transcription.
IFN was able to reduce VSV primary transcript accumulation
even in the PLSCR1/ (KO2) cells, perhaps because the
ISG(s) responsible for this effect was still induced, albeit to a
lower extent than in the PLSCR1-positive KI cells (Fig. 7).
Although expression of PLSCR1 was associated with modestly
enhanced IFN-induction of OAS2 (encoding a 2-5A syn-
thetase), there were no RNase L-mediated rRNA cleavage
products in IFN-treated, VSV-infected KI cells (data not
shown). Therefore, RNase L action against viral RNA is un-
likely to be responsible for the decreased accumulation of VSV
primary transcripts observed in the PLSCR1/ cells (data not
shown). The effect of PLSCR1 on a budding mutant of VSV
was also investigated. The N-terminal, cytoplasmic domain of
mPLSCR1 and hPLSCR1 contains PPXY motifs typical of
WW-binding domains that could potentially interfere with vi-
rus budding. These motifs are similar to the PY motif or
late-budding domain of the VSV M protein (PPPY) and of
other members of the Rhabdoviridae, Retroviridae, and Filov-
iridae (18). VSV yields were compared from KO2 and KI cells
infected with wild-type and mutant VSV in which the PPPY
budding domain of the M protein was altered to AAPA to
impair viral release (17, 23). However, yields of both wild-type
and mutant VSV were similarly decreased in the KI cells com-
pared with the KO2 cells (Fig. 9). These data suggest that,
irrespective of any potential antiviral effect of PLSCR1 at the
stage of virus assembly and budding from the plasma mem-
brane, PLSCR1 must also exert an inhibitory or antiviral action
prior to this terminal event in viral replication.
It was apparent from these studies that the observed antivi-
ral effect of PLSCR1 extended beyond VSV. Replication of
both VSV and EMCV were suppressed by expression of
PLSCR1 in the human Hey1B cell line. In PLSCR1/ MEFs,
an antiviral effect of ectopically expressed PLSCR1 was ob-
served against both VSV and the murine retrovirus Moloney
murine leukemia virus (Fig. 5 and data not shown). While our
results suggest that the broad antiviral effect mediated by
PLSCR1 is related to enhanced expression of certain antiviral
genes, the specific ISGs responsible for the inhibition of VSV,
EMCV, and Moloney murine leukemia virus replication ob-
served in this study are unknown. However, our findings indi-
cate that PLSCR1 is an amplifying factor in the expression of
certain critical antiviral genes that collectively have a large
impact on virus growth. Furthermore, our gene array results
provide a relatively short list of interesting candidate genes,
some of which are responsible for potent inhibition of viral
replication (Fig. 3). Exploring the specific functions of these
genes targeted by PLSCR1 will be a new direction for investi-
gating how IFNs protect cells against viral infections.
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